![Josh Mandel-Brehm](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Josh Mandel-Brehm
Direttore/Membro del Consiglio presso PROMIS NEUROSCIENCES, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Josh Mandel-Brehm is a Director at Vico Therapeutics BV, which he founded in 2019.
He is currently the President, Chief Executive Officer & Director at Camp4 Therapeutics Corp.
since 2017 and an Independent Director at ProMIS Neurosciences, Inc. since 2021.
Mr. Mandel-Brehm completed his undergraduate degree at Washington University in St. Louis and his MBA at the University of Michigan.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
15/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Josh Mandel-Brehm
Società | Posizione | Inizio |
---|---|---|
PROMIS NEUROSCIENCES, INC. | Direttore/Membro del Consiglio | 01/09/2021 |
Camp4 Therapeutics Corp.
![]() Camp4 Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom. | Amministratore Delegato | 01/05/2017 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Fondatore | 01/09/2019 |
Formazione di Josh Mandel-Brehm
University of Michigan | Masters Business Admin |
Washington University in St. Louis | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
PROMIS NEUROSCIENCES, INC. | Health Technology |
Aziende private | 2 |
---|---|
Camp4 Therapeutics Corp.
![]() Camp4 Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Health Technology |
- Borsa valori
- Insiders
- Josh Mandel-Brehm